KalVista Pharmaceuticals, Inc.

KALV

$27.00

Updated: 22/09/2026, 22:43:50

Market Cap

$1.44B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for KALV

Company Profile

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

USD

NASDAQ

CEO: Benjamin L. Palleiko

Employees: 275

https://www.kalvista.com

Asset Summaries

Latest generated summaries for KALV

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for KALV.

Share price: $27.00
Market cap: $1.44B
Exchange: NASDAQ
Currency: USD
CEO: Benjamin L. Palleiko
Employees: 275
IPO date: 09/04/2015
Beta: -0.29
Last dividend: $0.00
Day range: $26.98 – $27.00
52-week range: $9.83 – $27.00
1-day performance: 0.00%
1-year performance: 174.67%
Current drawdown (1Y): 0.00%
CIK: 0001348911
CUSIP: 483497103
ISIN: US4834971032
Created: 07/12/2025, 04:55:16
Last update: 22/09/2026, 22:43:50

Track KalVista Pharmaceuticals, Inc. with an AI analyst

See which prediction-market events move KALV, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to KALV from your Railway `news_articles` table.

Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

Business Wire • STOCK • 11/06/2026, 10:41:00

KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research • STOCK • 04/06/2026, 15:01:16

KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV

Business Wire • STOCK • 19/05/2026, 16:11:00

KalVista Pharmaceuticals (NASDAQ:KALV) Acquired by Chiesi Group in Strategic Rare Disease Expansion

Market Data • Market Data • 30/04/2026, 04:11:56

KalVista Pharmaceuticals (NASDAQ: KALV) Downgraded by Citigroup Amid Acquisition and EKTERLY's Strong Launch

Market Data • Market Data • 29/04/2026, 21:14:23

Shareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

PRNewsWire • STOCK • 29/04/2026, 14:17:00

KalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case Alive

Seeking Alpha • STOCK • 07/04/2026, 08:11:43

KalVista Pharmaceuticals, Inc. (KALV) 8 Months 2025 Earnings Call Transcript

Seeking Alpha • STOCK • 25/03/2026, 15:55:54